Clinical features of external genital warts

Journal of Cutaneous Medicine and Surgery

Volumn 17, Issue SUPPL 2, 2013, Pages

  Lynde, Charles ^a   Vender, Ronald ^b   Bourcier, Marc ^c   Bhatia, Neal ^d  

^a UNIVERSITY OF TORONTO   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF SHERBROOKE   (Canada)

^d HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GREEN TEA EXTRACT; IMIQUIMOD; PODOPHYLLOTOXIN; TRICHLOROACETIC ACID;

AGE DISTRIBUTION; ANUS CANCER; ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONDYLOMA ACUMINATUM; CRYOTHERAPY; DISEASE ASSOCIATION; DISEASE COURSE; DYSPAREUNIA; ELECTROSURGERY; HUMAN; INCIDENCE; INCUBATION TIME; LOW LEVEL LASER THERAPY; PENIS CANCER; PRIORITY JOURNAL; RISK ASSESSMENT; SEX DIFFERENCE; SKIN BIOPSY; SYMPTOMATOLOGY; UTERINE CERVIX CANCER; VIRUS DETECTION; VIRUS STRAIN; VIRUS TYPING; VULVOVAGINAL DISEASE;

ANTIVIRAL AGENTS; CONDYLOMATA ACUMINATA; FEMALE; HUMANS; PAPILLOMAVIRIDAE; UTERINE CERVICAL DISEASES; VAGINAL SMEARS;

EID: 84892564315     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.2310/7750.2013.13073     Document Type: Article

References (30)

1. Garland S, Steben M, Sings HL, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis 2009;119: 805-14, doi:10.1086/597071.
2. Buck HW. Warts (genital). Clin Evid (Online) 2010;2010 pii: 1602.
3. Centers for Disease Control and Prevention. Sexually transmitted diseases guidelines 2010. MMWR Morb Mortal Wkly Rep 2010;59 (No. RR-12): 69-74.
4. Burd EM. Human papillomavirus and cervical cancer. Clin Microbiol Rev 2003;16: 1-17, doi:10.1128/CMR.16.1.1-17.2003. (Pubitemid 36114705)
5. Cardoso JC, Calonie E. Cutaneous manifestations of human papillomaviruses: a review. Acta Dermatoven APA 2011;20: 145-54.
6. Yanofsky VR, Patel RV, Goldenberg G. Genital warts: a comprehensive review. J Clin Aesthet Dermatol 2012;5: 25-36.
7. Centers for Disease Control and Prevention. Human papillomavirus: HPV information for clinicians. November 2006. Available at: http://www.cdc.gov/std/ HPV/hpv-clinicians-brochure.htm (accessed May 1, 2013).
8. Handsfield HH. Clinical presentation and natural course of anogenital warts. Am J Med 1997;102(5A): 16-20, doi:10.1016/S0002-9343(97)00179-4. (Pubitemid 127695955)
9. Wiley DJ, Douglas J, Beutner K, et al. External genital warts: diagnosis, treatment, and prevention. Clin Infect Dis 2002;35 Suppl 2:S210-24, doi:10.1086/342109. (Pubitemid 35178333)
10. Cox JT. Epidemiology and natural history of HPV. J Fam Pract 2006;Suppl: 3-9. (Pubitemid 44737192)
11. Marra F, Ogilvie G, Colley L, et al. Epidemiology and costs associated with genital warts in Canada. Sex Transm Infect 2009; 85: 111-5, doi:10.1136/sti.2008.030999.
12. Kliewer EV, Demers AA, Elliot L, et al. Twenty-year trends in the incidence and prevalence of diagnosed anogenital warts in Canada. Sex Transm Dis 2009;36: 380-6, doi:10.1097/OLQ.0b013e318198de8c.
13. Revzina NV, Diclemente RJ. Prevalence and incidence of human papillomavirus infection in women in the USA: a systematic review. Int J STD AIDS 2005;16: 528-37, doi:10.1258/0956462054679214. (Pubitemid 41192302)
14. Nielson CM, Harris RB, Flores R, et al. Multiple-type human papillomavirus infection in male anogenital sites: prevalence and associated factors. Cancer Epidemiol Biomarkers Prev 2009;18: 1077-83, doi:10.1158/1055- 9965.EPI-08-0447.
15. Nielson CM, Flores R, Harris RB, et al. Human papillomavirus prevalence and type distribution in male anogenital sites and semen. Cancer Epidemiol Biomarkers Prev 2007;16: 1107-14, doi:10.1158/1055-9965.EPI-06-0997. (Pubitemid 46984945)
16. Baseman JG, Koutsky LA. The epidemiology of the human papillomavirus. J Clin Virol 2005;32 Suppl 1:S16-24, doi:10.1016/j.jcv. 2004.12.008.
17. Public Health Agency of Canada. Canada Communicable Disease Report. Update on human papillomavirus (HPV) vaccines. January 2012, Volume 38, ACS-1. Available at: http://www.phac-aspc. gc.ca/publicat/ccdr-rmtc/12vol38/acs-dcc-1/ index-eng.php (accessed October 13, 2013).
18. de Sanjose S, Diaz M, Castellsague X, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 2007;7: 453-9, doi:10.1016/S1473- 3099(07)70158-5. (Pubitemid 46962343)
19. Scheinfeld N, Lehman DS. An evidence-based review of medical and surgical treatments of genital warts. Dermatol Online J 2006;12 (3): 5.
20. Gunter J. Genital and perianal warts: new treatment opportunities for human papillomavirus infection. Am J Obstet Gynecol 2003; 189(3 Suppl):S3-11.
21. Wilson JD, Brown CB, Walker PP. Factors involved in clearance of genital warts. Int J STD AIDS 2001;12: 789-92, doi:10.1258/0956462011924407. (Pubitemid 33135684)
22. Beutner KR, Reitano MV, Wiley DJ, et al. External genital warts: report of the American Medical Association Consensus Conference. Clin Infect Dis 1998;27: 796-806, doi:10.1086/514964. (Pubitemid 29244337)
23. Gunter J. Genital and perianal warts: new treatment opportunities for human papillomavirus infection. Am J Obstet Gynecol 2003; 189(3 Suppl):S3-11, doi:10.1067/S0002-9378(03)00789-0. (Pubitemid 37194064)
24. von Krogh G, Lacey CJ, Gross G, et al. European course on HPV associated pathology: guidelines for primary care physicians for the diagnosis and management of anogenital warts. Sex Transm Infect 2000;76: 162-8, doi:10.1136/sti.76.3.162. (Pubitemid 30435195)
25. Stanley MA. Epithelial cell responses to infection with human papillomavirus. Clin Microbiol Rev 2012;25: 215-22, doi:10.1128/CMR.05028-11.
26. Grabowska AK, Riemer AB. The invisible enemy - how human papillomaviruses avoid recognition and clearance by the host immune system. Open Virol J 2012;6: 249-56, doi:10.2174/1874 357901206010249.
27. Gormley RH, Kovarik CL. Human papillomavirus-related genital disease in the immunocompromised host, part I. J Am Acad Dermatol 2012;66: 867.e1-14, doi:10.1016/j.jaad.2010.12.050.
28. Winer RL, Kiviat NB, Hughes JP, et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis 2005;191: 731-8, doi:10.1086/427557. (Pubitemid 40271061)
29. Ho GY, Bierman R, Beardsley L, et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338: 423-8, doi:10.1056/NEJM199802123380703. (Pubitemid 28135669)
30. Public Health Agency of Canada. Genital human papillomavirus (HPV) infections, Canadian STI guidelines, 2008. Available at: http://www.phac-aspc. gc.ca/std-mts/sti-its/cgsti-ldcits/section-5-5- eng.php#footnote43 (accessed October 13, 2013).